In the US, Zontivity (vorapaxar systemic) is a member of the drug class protease-activated receptor-1 antagonists and is used to treat Peripheral Arterial Disease, Prevention of Atherothrombotic Events and Thromboembolic Disorder.
Ingredient matches for Zontivity
Vorapaxar sulfate (a derivative of Vorapaxar) is reported as an ingredient of Zontivity in the following countries:
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.